Menopause and ageing in women with multiple sclerosis
Clinical Scorecard: The Impact of Menopause and Ageing on Women Diagnosed with Multiple Sclerosis
At a Glance
| Category | Detail |
|---|
| Condition | Multiple Sclerosis (MS) |
| Key Mechanisms | Interaction of menopause and biological ageing affecting inflammatory activity, disability progression, and symptom burden. |
| Target Population | Women diagnosed with MS, particularly those who are peri- or postmenopausal. |
| Care Setting | Clinical management of MS in midlife women. |
Key Highlights
- Menopause does not appear to be a clear inflection point for MS relapse activity or progression.
- Symptom burden often worsens during midlife due to hormonal changes and comorbidities.
- Menopausal hormone therapy may alleviate symptoms but its effect on disease progression is uncertain.
- Women in peri- and postmenopausal stages constitute approximately one third of the MS population.
- A menopause-aware approach is necessary for optimizing MS management in ageing women.
Guideline-Based Recommendations
Diagnosis
- Menopause is diagnosed retrospectively after 12 months of amenorrhoea.
Management
- Consider the overlapping effects of menopause and MS-related symptoms in clinical management.
Monitoring & Follow-up
- Monitor symptom burden and comorbidities in midlife women with MS.
Risks
- Increased neuroaxonal vulnerability may be associated with reproductive ageing.
Patient & Prescribing Data
Women with MS, particularly those in peri- and postmenopausal stages.
Limited evidence supports the use of menopausal hormone therapy for symptom relief without clear impact on disease course.
Clinical Best Practices
- Adopt a menopause-aware approach in MS care.
- Avoid misattribution of symptoms to menopause without considering MS-related factors.
- Recognize the complexity of hormonal changes and their interaction with MS symptoms.
Related Resources & Content
